Clash of the titans: interferons and SARS-CoV-2

Interferons are our first line of defense against invading viruses. However, viruses encode effector proteins that can modulate human interferon responses. In this forum article, we highlight important discoveries and discuss outstanding questions that will enable us to better understand the nuances...

Descripción completa

Detalles Bibliográficos
Autores principales: Jouvenet, Nolwenn, Goujon, Caroline, Banerjee, Arinjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519778/
https://www.ncbi.nlm.nih.gov/pubmed/34742657
http://dx.doi.org/10.1016/j.it.2021.10.009
_version_ 1784584523053268992
author Jouvenet, Nolwenn
Goujon, Caroline
Banerjee, Arinjay
author_facet Jouvenet, Nolwenn
Goujon, Caroline
Banerjee, Arinjay
author_sort Jouvenet, Nolwenn
collection PubMed
description Interferons are our first line of defense against invading viruses. However, viruses encode effector proteins that can modulate human interferon responses. In this forum article, we highlight important discoveries and discuss outstanding questions that will enable us to better understand the nuances of this evolutionary battle between interferons and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
format Online
Article
Text
id pubmed-8519778
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85197782021-10-18 Clash of the titans: interferons and SARS-CoV-2 Jouvenet, Nolwenn Goujon, Caroline Banerjee, Arinjay Trends Immunol Forum Interferons are our first line of defense against invading viruses. However, viruses encode effector proteins that can modulate human interferon responses. In this forum article, we highlight important discoveries and discuss outstanding questions that will enable us to better understand the nuances of this evolutionary battle between interferons and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Elsevier Ltd. 2021-12 2021-10-16 /pmc/articles/PMC8519778/ /pubmed/34742657 http://dx.doi.org/10.1016/j.it.2021.10.009 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Forum
Jouvenet, Nolwenn
Goujon, Caroline
Banerjee, Arinjay
Clash of the titans: interferons and SARS-CoV-2
title Clash of the titans: interferons and SARS-CoV-2
title_full Clash of the titans: interferons and SARS-CoV-2
title_fullStr Clash of the titans: interferons and SARS-CoV-2
title_full_unstemmed Clash of the titans: interferons and SARS-CoV-2
title_short Clash of the titans: interferons and SARS-CoV-2
title_sort clash of the titans: interferons and sars-cov-2
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519778/
https://www.ncbi.nlm.nih.gov/pubmed/34742657
http://dx.doi.org/10.1016/j.it.2021.10.009
work_keys_str_mv AT jouvenetnolwenn clashofthetitansinterferonsandsarscov2
AT goujoncaroline clashofthetitansinterferonsandsarscov2
AT banerjeearinjay clashofthetitansinterferonsandsarscov2

Ejemplares similares